Your browser doesn't support javascript.
loading
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Pleyer, Lisa; Döhner, Hartmut; Dombret, Hervé; Seymour, John F; Schuh, Andre C; Beach, C L; Swern, Arlene S; Burgstaller, Sonja; Stauder, Reinhard; Girschikofsky, Michael; Sill, Heinz; Schlick, Konstantin; Thaler, Josef; Halter, Britta; Machherndl Spandl, Sigrid; Zebisch, Armin; Pichler, Angelika; Pfeilstöcker, Michael; Autzinger, Eva M; Lang, Alois; Geissler, Klaus; Voskova, Daniela; Sperr, Wolfgang R; Hojas, Sabine; Rogulj, Inga M; Andel, Johannes; Greil, Richard.
Afiliación
  • Pleyer L; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University, Salzburg 5020, Austria. l.pleyer@salk.at.
  • Döhner H; Cancer Cluster, Salzburg 5020, Austria. l.pleyer@salk.at.
  • Dombret H; Department of Medicine and Internal Medicine III, Universitätsklinikum Ulm, Ulm D-89081, Germany. hartmut.doehner@uniklinik-ulm.de.
  • Seymour JF; Institut Universitaire d'Hématologie, Hôpital Saint Louis, University Paris Diderot, Paris 75010, France. herve.dombret@mac.com.
  • Schuh AC; Peter MacCallum Cancer Centre, East Melbourne, Australia, and University of Melbourne, Parkville 3000, Australia. john.seymour@petermac.org.
  • Beach CL; Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada. andre.schuh@uhn.ca.
  • Swern AS; Celgene Corporation, Summit, NJ 07901, USA. clbeach@celgene.com.
  • Burgstaller S; Celgene Corporation, Summit, NJ 07901, USA. aswern@celgene.com.
  • Stauder R; Department of Internal Medicine IV, Klinikum WelsGrieskirchen, Wels 4600, Austria. sonja.burgstaller@klinikum-wegr.at.
  • Girschikofsky M; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck 6020, Austria. reinhard.stauder@i-med.ac.at.
  • Sill H; Department of Hematology and Oncology, Elisabethinen Hospital, Linz 4020, Austria. michael.girschikofsky@elisabethinen.or.at.
  • Schlick K; Department of Hematology, Medical University of Graz, Graz 8036, Austria. heinz.sill@medunigraz.at.
  • Thaler J; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University, Salzburg 5020, Austria. k.schlick@salk.at.
  • Halter B; Department of Internal Medicine IV, Klinikum WelsGrieskirchen, Wels 4600, Austria. josef.thaler@klinikum-wegr.at.
  • Machherndl Spandl S; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck 6020, Austria. britta.halter@i-med.ac.at.
  • Zebisch A; Department of Hematology and Oncology, Elisabethinen Hospital, Linz 4020, Austria. sigrid.machherndl-spandl@elisabethinen.or.at.
  • Pichler A; Department of Hematology, Medical University of Graz, Graz 8036, Austria. armin.zebisch@medunigraz.at.
  • Pfeilstöcker M; Department for Hematology and Oncology, LKH Leoben, Leoben 8700, Austria. angelika.pichler@kages.at.
  • Autzinger EM; 3rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna 1140, Austria. m.pfeilstoecker@aon.at.
  • Lang A; First Medical Department, Center for Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna 1160, Austria. eva-maria.autzinger@wienkav.at.
  • Geissler K; Department of Internal Medicine, Landeskrankenhaus Feldkirch (LKH) Feldkirch, Feldkirch 6800, Austria. alois.lang@lkhf.at.
  • Voskova D; 5th Medical Department, Hospital Hietzing, Vienna 1130, Austria. klaus.geissler@wienkav.at.
  • Sperr WR; Department of Internal Medicine III, General Hospital, Linz 4020, Austria. daniela.voskova@gmail.com.
  • Hojas S; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna 1090, Austria. wolfgang.r.sperr@meduniwien.ac.at.
  • Rogulj IM; Department of Internal Medicine, LKH Fürstenfeld, Fürstenfeld 8280, Austria. sabineelisabeth.hojas@kages.at.
  • Andel J; Department of Hematology, Clinical Hospital Merkur, Zagreb 10000, Croatia. imandac@yahoo.com.
  • Greil R; Department of Internal Medicine II, LKH Steyr, Steyr 4400, Austria. johannes.andel@gespag.at.
Int J Mol Sci ; 18(2)2017 Feb 15.
Article en En | MEDLINE | ID: mdl-28212292
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Azacitidina / Leucemia Mieloide Aguda / Antimetabolitos Antineoplásicos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Int J Mol Sci Año: 2017 Tipo del documento: Article País de afiliación: Austria
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Azacitidina / Leucemia Mieloide Aguda / Antimetabolitos Antineoplásicos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Int J Mol Sci Año: 2017 Tipo del documento: Article País de afiliación: Austria